Track topics on Twitter Track topics that are important to you
MBC Pharma Inc., a privately held biopharmaceutical company announced today, that it has been awarded an $594,202 Phase I Small Business Innovation Research (SBIR) grant from the U.S. National Institutes of Health. MBC will use this 2-year grant to expand their discovery pipeline to include bone-targeted antibiotics for the treatment of osteomyelitis and other bone infections. The work will focus on the synthesis and efficacy testing of novel bone-targeted conjugates of agents with known anti-infective activities.
MBC Pharma is a privately held pharmaceutical company developing bone targeted therapeutics for serious diseases and conditions of bone with an oncology and anti-infectives focus.
For information on MBC Pharma please contact Dr. Alexander Karpeisky at 720-859-4041 or Dr. Shawn Zinnen at 720-859-4040NEXT ARTICLE
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...
Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...